暫無數據
代碼股票名稱
最新價漲跌額漲跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日漲跌幅10日漲跌幅20日漲跌幅60日漲跌幅120日漲跌幅250日漲跌幅年初至今漲跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業
美股期權個股詳情
IMMP240517C2500
- 0.55
- +0.25+83.33%
延時15分鐘行情收盤價 05/17 15:58 (美東)
0.55最高價0.55最低價
0.55今開0.30昨收5張成交量752張未平倉合約數2.50行權價275.00成交額2909.23%引伸波幅3.04%溢價2024/05/17到期日0.46内在价值100合約乘數0天距到期日0.09時間價值100合約規模美式期權類型0.7969Delta0.4024Gamma5.38槓桿倍數-4.1399Theta0.0000Rho4.29有效槓桿0.0001Vega
分時
- 5日
- 日K
新聞
Immutep(IMMP.US)獲Capital One首次覆蓋，給予增持評級, 目標價10.00美元。
Immutep(IMMP.US)獲Capital One首次覆蓋，給予增持評級, 目標價10.00美元。
由Capital One發起增持的Immutep
由Capital One發起增持的Immutep
快訊 | Capital One以增持評級啓動對Immutep的報道，宣佈目標股價爲10美元
Immutep 分析師評級
日期上行/下行分析師公司目標股價變動評級變動之前/當前評級 2024 年 5 月 17 日 233.33% Capital One → 10 美元啓動承保 → 增持 2023 年 8 月 28 日 133.33% Baird → 7 美元房地產投資信託基金
對Immutep的Efti的買入評級：具有巨大市場潛力的腫瘤學治療前景
Immutep宣佈了令人鼓舞的癌症試驗結果
評論
$Immutep(IMMP.US$ Data From Safety Lead-in Phase of AIPAC-003 Confirmed Complete Response In A Patient With Metastatic Breast Cancer Refractory To Several Lines Of Therapy Achieved During Combination Treatment With 90mg Efti And Paclitaxel
Benzinga· 3 mins ago
Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces encouraging efficacy, safety,...
Benzinga· 3 mins ago
Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces encouraging efficacy, safety,...
$Immutep(IMMP.US$ Initial Clinical Data Reported From Immutep's Efti Combined With Radiotherapy And Checkpoint Inhibitor From Phase II Trial In Soft Tissue Sarcoma
Benzinga· 2 mins ago
Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial
Four of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are rarely observed with...
Benzinga· 2 mins ago
Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial
Four of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are rarely observed with...
$Immutep(IMMP.US$ Immutep Announced Tuesday, Data From Efti In Combination With Keytruda In First Line Head And Neck Squamous Cell Carcinoma Patients Who Do Not Express PD-L1 Shows A Preliminary 26.9% Response Rate, The Primary Endpoint Of The Study
Benzinga· 7 mins ago
Benzinga· 7 mins ago
$Immutep(IMMP.US$ Immutep Announced Tuesday, Positive Feedback From Spanish Medicines Agency For Upcoming TACTI-004 Registrational Trial In Metastatic Non-Small Cell Lung Cancer
閱讀更多